Dr. Sameer A. Parikh, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 277
Licensed in Texas since 2005, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MN license 53635 -
Hematology & Oncology Physician
MN license 53635 -
Internal Medicine Physician
MN license 53635 · TX license M2001 (first issued 2005; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
- Mayo Clinic Health System - Mankato Mankato, MN
- Mayo Clinic Health System - Albert Lea and Austin Albert Lea, MN
- Mayo Clinic Health System in Red Wing Red Wing, MN
- Mayo Clinic Health System - Cannon Falls Cannon Falls, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 277
- Services billed
- 14,535
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 147 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 71 | 61 |
| Established patient office or other outpatient visit, 40-54 minutes | 54 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imbruvica (ibrutinib) | 67 |
| Venclexta (venetoclax) | 65 |
| Acyclovir Other prescribers in Rochester, MN | 52 |
| Calquence (acalabrutinib maleate) | 51 |
| Brukinsa (zanubrutinib) | 22 |
| Jaypirca (pirtobrutinib) | 19 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Rochester, MN | 16 |
| Prochlorperazine Maleate Other prescribers in Rochester, MN | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 13 payments worth $33,501 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $11,890 |
|---|---|
| Merck Sharp & Dohme LLC | $9,791 |
| AbbVie Inc. | $7,585 |
| Sobi, Inc | $4,235 |
| Consulting Fee | $33,291 |
|---|---|
| Travel and Lodging | $136 |
| Food and Beverage | $74.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Consulting Fee CALQUENCE · Oncology | $4,920 |
| Sobi, Inc Jun 23, 2025 | Consulting Fee Gamifant · Hematology | $4,235 |
| AstraZeneca Pharmaceuticals LP Aug 1, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| Merck Sharp & Dohme LLC May 7, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,660 |
| Merck Sharp & Dohme LLC Jan 8, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,355 |
| AbbVie Inc. May 8, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,875 |
| AstraZeneca Pharmaceuticals LP Dec 17, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,870 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $2,440 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,400 |
| AbbVie Inc. Jul 29, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,100 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 17, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,870 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $2,440 |
| Merck Sharp & Dohme LLC Aug 6, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $336 |
| AstraZeneca Pharmaceuticals LP Aug 1, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| AbbVie Inc. Jul 29, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,100 |
| AbbVie Inc. Jul 29, 2025 | Travel and Lodging VENCLEXTA · ONCOLOGY · travel to TRETORRI, Italy · in-kind | $136 |
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Consulting Fee CALQUENCE · Oncology | $4,920 |
| Sobi, Inc Jun 23, 2025 | Consulting Fee Gamifant · Hematology | $4,235 |
| AbbVie Inc. May 8, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,875 |
| Merck Sharp & Dohme LLC May 7, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,660 |
| Merck Sharp & Dohme LLC Jan 8, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $3,355 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $11,167,879 in research payments for these studies, mostly to the institutions running them.
- A randomized phase 2 study comparing acalabrutinib to acalabrutinib and obinutuzumab in the treatment of patients with early-stage CLL/SLL who are at high risk of disease progression.
AstraZeneca Pharmaceuticals LP - A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Beone Medicines Ltd. · Recruiting · NCT06943872 - Safety Efficacy and Pharmacokinetics of Mosunetuzumab in R R CLL
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.